Thursday, November 5, 2026

W.W. Grainger, Inc. And 3 Other Stocks Have Very High Payout Ratio

ViaNews Editorial Team

January 20, 2021

W.W. Grainger, Inc. And 3 Other Stocks Have Very High Payout Ratio

We have congregated information about stocks with the highest payout ratio at the moment. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

When researching a potential investment, the dividend payout ratio is a good statistic to know and anything around 60 percent is considered high.

1. NorthWestern Corporation

74.45% Payout Ratio

NorthWestern Corporation, doing business as NorthWestern Energy, provides electricity and natural gas to residential, commercial, and industrial customers.

As claimed by Morningstar, Inc., the next dividend payment is on Dec 13, 2020, the estimated forward annual dividend rate is 2.4 and the estimated forward annual dividend yield is 4.17%.

NorthWestern Corporation's sales growth this year is anticipated to be negative 0.7% and 3.4% for next year.

Year-on-year quarterly revenue growth grew by 2.1%, now sitting on 1.21B for the twelve trailing months.

NorthWestern Corporation's sales growth is 10.4% for the current present quarter and 12.8% for the next. The company's growth estimates for the current quarter and the next is 8.4% and 14%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.96%.

Volatility

NorthWestern Corporation's last day, last week, and last month's average volatility was a negative 1.07%, a negative 0.48%, and a positive 0.01%, respectively.

NorthWestern Corporation's last day, last week, and last month's high and low average amplitude percentage was 2.18%, 3.08%, and 2.62%, respectively.

NorthWestern Corporation's Stock Yearly Top and Bottom Value

NorthWestern Corporation's stock is valued at $56.92 at 04:23 EST, way below its 52-week high of $65.38 and way above its 52-week low of $47.43.

NorthWestern Corporation's Moving Average

NorthWestern Corporation's value is under its 50-day moving average of $57.48 and higher than its 200-day moving average of $54.41.

2. Medical Properties Trust, Inc.

121.59% Payout Ratio

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities.

As stated by Morningstar, Inc., the next dividend payment is on Dec 8, 2020, the estimated forward annual dividend rate is 1.08 and the estimated forward annual dividend yield is 5.27%.

Medical Properties Trust, Inc.'s sales growth this year is anticipated to be 45.7% and 11.6% for next year.

Year-on-year quarterly revenue growth grew by 46.9%, now sitting on 1.19B for the twelve trailing months.

Medical Properties Trust, Inc.'s sales growth is 29% for the present ongoing quarter and 10% for the next. The company's growth estimates for the present quarter and the next is 3.8% and 73.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.85%.

Volatility

Medical Properties Trust, Inc.'s last day, last week, and last month's average volatility was a positive 2.83%, a negative 0.69%, and a positive 0.05%, respectively.

Medical Properties Trust, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.68%, 3.02%, and 2.16%, respectively.

Medical Properties Trust, Inc.'s Stock Yearly Top and Bottom Value

Medical Properties Trust, Inc.'s stock is valued at $21.07 at 04:23 EST, way below its 52-week high of $24.29 and way above its 52-week low of $12.35.

Medical Properties Trust, Inc.'s Moving Average

Medical Properties Trust, Inc.'s value is above its 50-day moving average of $20.70 and way higher than its 200-day moving average of $19.08.

3. BancFirst Corporation

43.19% Payout Ratio

BancFirst Corporation operates as the bank holding company for BancFirst that provides a range of commercial banking services to retail customers, and small to medium-sized businesses.

As maintained by Morningstar, Inc., the next dividend payment is on Dec 29, 2020, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 2.18%.

BancFirst Corporation's sales growth this year is anticipated to be 5.2% and a negative 1.7% for next year.

Year-on-year quarterly revenue growth declined by 12.8%, now sitting on 379.33M for the twelve trailing months.

BancFirst Corporation's sales growth is 2.2% for the current current quarter and 7% for the next. The company's growth estimates for the current quarter and the next is negative 32.1% and 42.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.86%.

Volatility

BancFirst Corporation's last day, last week, and last month's average volatility was a negative 1.65%, a positive 1.31%, and a positive 0.34%, respectively.

BancFirst Corporation's last day, last week, and last month's high and low average amplitude percentage was 4.35%, 4.40%, and 3.45%, respectively.

BancFirst Corporation's Stock Yearly Top and Bottom Value

BancFirst Corporation's stock is valued at $62.48 at 04:23 EST, under its 52-week high of $64.80 and way above its 52-week low of $26.00.

BancFirst Corporation's Moving Average

BancFirst Corporation's worth is higher than its 50-day moving average of $57.92 and way above its 200-day moving average of $46.98.

4. W.W. Grainger, Inc.

50.34% Payout Ratio

W.W. Grainger, Inc. distributes maintenance, repair, and operating (MRO) products and services in the United States, Canada, and internationally.

According to Morningstar, Inc., the next dividend payment is on Nov 5, 2020, the estimated forward annual dividend rate is 6.12 and the estimated forward annual dividend yield is 1.53%.

W.W. Grainger, Inc.'s sales growth this year is anticipated to be 2.5% and 3.9% for next year.

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 11.7B for the twelve trailing months.

W.W. Grainger, Inc.'s sales growth is 2.4% for the current ongoing quarter and negative 0.1% for the next. The company's growth estimates for the ongoing quarter and the next is negative 1.5% and 5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.9%.

Volatility

W.W. Grainger, Inc.'s last day, last week, and last month's average volatility was a negative 0.84%, a negative 0.59%, and a negative 0.12%, respectively.

W.W. Grainger, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 4.08%, 2.98%, and 2.03%, respectively.

W.W. Grainger, Inc.'s Stock Yearly Top and Bottom Value

W.W. Grainger, Inc.'s stock is valued at $396.68 at 04:23 EST, under its 52-week high of $427.90 and way higher than its 52-week low of $200.61.

W.W. Grainger, Inc.'s Moving Average

W.W. Grainger, Inc.'s value is below its 50-day moving average of $408.35 and higher than its 200-day moving average of $366.21.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com